A Kidney-Microbiome Short- and Medium-Chain Fatty Acid Loop Mediated by OAT1: Implications for the Remote Sensing and Signaling Theory
Renal transporter OAT1 forms a bidirectional feedback loop with gut microbiota through short- and medium-chain fatty acid metabolism.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
Oat1 knockout mice showed marked disruption of propionate synthesis pathways in the gut microbiome, whereas Oat3 knockout had minimal effect. Serum propionate derivatives and 3-hydroxybutyrate were OAT1-dependent in both mouse knockouts and humans treated with probenecid. The Oat1 knockout gut microbiome also displayed increased fatty acid synthesis, producing odd-chain fatty acids such as heptanoate.
How it was done
Experimental study combining fecal metagenomics and serum metabolomics in Oat1 and Oat3 knockout mice, with translational validation in humans exposed to probenecid, an OAT1 inhibitor.
Risk of bias
The abstract does not report sample sizes, full design of the human arm, or clinical endpoints; functional extrapolations to humans remain speculative based on the available summary.
What this study does NOT prove
The study does not prove that modulating OAT1 or gut microbiota produces clinical benefit in kidney disease.
In clinical practice
No clinical recommendation is supported by this study; findings are mechanistic and preclinical with an exploratory translational component.
Limitations
The abstract does not report sample sizes, full design of the human arm, or clinical endpoints; functional extrapolations to humans remain speculative based on the available summary.
Technical appendix
Version history
- 1.0 · 2026-07-27 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.